Zacks Research Equities Analysts Increase Earnings Estimates for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHFree Report) – Stock analysts at Zacks Research raised their Q1 2024 EPS estimates for Deciphera Pharmaceuticals in a research note issued on Tuesday, January 30th. Zacks Research analyst A. Chakraborty now forecasts that the company will earn ($0.61) per share for the quarter, up from their prior forecast of ($0.62). The consensus estimate for Deciphera Pharmaceuticals’ current full-year earnings is ($2.34) per share. Zacks Research also issued estimates for Deciphera Pharmaceuticals’ Q2 2024 earnings at ($0.62) EPS, Q3 2024 earnings at ($0.61) EPS, Q4 2024 earnings at ($0.57) EPS, FY2024 earnings at ($2.41) EPS, Q1 2025 earnings at ($0.57) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.38) EPS and FY2025 earnings at ($1.93) EPS.

A number of other equities analysts also recently commented on the company. Jonestrading raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 31st. HC Wainwright boosted their price objective on Deciphera Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. JPMorgan Chase & Co. reissued a “neutral” rating and set a $14.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Monday, November 20th. Piper Sandler raised Deciphera Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $18.00 to $23.00 in a report on Monday, October 30th. Finally, Stifel Nicolaus upped their price target on Deciphera Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Deciphera Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $23.67.

Check Out Our Latest Report on Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Stock Performance

Shares of Deciphera Pharmaceuticals stock opened at $14.32 on Thursday. Deciphera Pharmaceuticals has a one year low of $9.90 and a one year high of $18.00. The company has a market cap of $1.15 billion, a PE ratio of -6.09 and a beta of 0.46. The business has a 50-day simple moving average of $14.73 and a 200-day simple moving average of $13.52.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Free Report) last announced its quarterly earnings data on Monday, October 30th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.03. Deciphera Pharmaceuticals had a negative return on equity of 49.41% and a negative net margin of 127.92%. The business had revenue of $43.31 million during the quarter, compared to the consensus estimate of $39.66 million. During the same period in the previous year, the company posted ($0.55) earnings per share.

Insider Activity at Deciphera Pharmaceuticals

In other news, EVP Matthew L. Sherman sold 2,435 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $14.47, for a total value of $35,234.45. Following the completion of the sale, the executive vice president now directly owns 94,079 shares of the company’s stock, valued at $1,361,323.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.43% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

Several large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Deciphera Pharmaceuticals by 20.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,178 shares of the company’s stock valued at $196,000 after acquiring an additional 2,102 shares during the period. Cornercap Investment Counsel Inc. boosted its holdings in shares of Deciphera Pharmaceuticals by 24.6% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 16,673 shares of the company’s stock valued at $269,000 after acquiring an additional 3,294 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Deciphera Pharmaceuticals by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock valued at $670,000 after acquiring an additional 1,117 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $818,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Deciphera Pharmaceuticals by 357.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,272 shares of the company’s stock worth $150,000 after purchasing an additional 7,246 shares during the last quarter. 70.96% of the stock is owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

(Get Free Report)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Featured Articles

Earnings History and Estimates for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.